Schwartzberg, Barbara
Lewin, John
Abdelatif, Osama
Bernard, Jacqueline
Bu-Ali, Hanadi
Cawthorn, Simon
Chen-Seetoo, Margaret
Feldman, Sheldon
Govindarajulu, Sasirekha
Jones, Lyn
Juette, Arne
Kavia, Sanjay
Maganini, Robert
Pain, Simon
Shere, Mike
Shriver, Craig
Smith, Simon
Valencia, Alexandra
Whitacre, Eric
Whitney, Roger
Funding for this research was provided by:
Novian Health, Inc., Chicago, Illinois (BR-002 (NCT01478438))
Article History
Received: 23 April 2018
First Online: 9 July 2018
Change Date: 8 October 2018
Change Type: Correction
Change Date: 8 October 2018
Change Type: Correction
Change Type: Correction
Change Details: The article “Phase 2 Open-Label Trial Investigating Percutaneous Laser Ablation for Treatment of Early-Stage Breast Cancer: MRI, Pathology, and Outcome Correlations”, written by Barbara Schwartzberg et al., was originally published electronically on the publisher’s internet portal (currently SpringerLink) on July 9, 2018, without open access.
Change Details: The article ?Phase 2 Open-Label Trial Investigating Percutaneous Laser Ablation for Treatment of Early-Stage Breast Cancer: MRI, Pathology, and Outcome Correlations?, written by Barbara Schwartzberg et al., was originally published electronically on the publisher?s internet portal (currently SpringerLink) on July 9, 2018, without open access.
Change Date: 8 October 2018
Change Details: The article ?Phase 2 Open-Label Trial Investigating Percutaneous Laser Ablation for Treatment of Early-Stage Breast Cancer: MRI, Pathology, and Outcome Correlations?, written by Barbara Schwartzberg et al., was originally published electronically on the publisher?s internet portal (currently SpringerLink) on July 9, 2018, without open access.
Disclosure
: Dr. Schwartzberg is a consultant for Novian Health and the principal investigator in this trial.